Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have diffuse large B-cell lymphoma that is CD20-positive (a specific marker on the cancer cells).
- You have tried at least two standard treatments, including certain chemotherapy and anti-CD20 therapy, or had a stem cell transplant, but the cancer came back or didn't respond.
- You have at least one tumor that can be measured on a CT or PET scan.
- You are in fairly good health otherwise, with an ECOG performance status of 0 or 1 (able to do daily activities).
- You have not had a prior treatment with any genetically engineered T-cell or cell-gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
This trial tests a new treatment called JWCAR201, which uses your own immune cells (a type of CAR-T therapy) to fight either certain blood cancers (large B cell lymphoma) or autoimmune disease (lupus). The goal is to see if this cell therapy can help when standard treatments haven't worked.
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
This trial tests an experimental treatment called JWCAR239, which uses your own immune cells (T cells) that are modified in a lab to find and kill lymphoma cells. It is for people with certain types of B cell lymphoma that have come back or not responded to at least two prior treatments.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.